



14<sup>th</sup>

International Donor Registry Conference  
& WMDA Meetings

25 – 29 June, 2024 – Cape Town, South Africa

*All patients & donors matter*

[www.capetownidrc.co.za](http://www.capetownidrc.co.za)

Advancing and facilitating the research, development and equitable clinical application of cell and gene therapies - what is our role in this?

Moderators: Salmah Ahmed, Jay Feinberg





14<sup>th</sup>

International Donor Registry Conference  
& WMDA Meetings

25 – 29 June, 2024 – Cape Town, South Africa


*All patients & donors matter*

[www.capetownidrc.co.za](http://www.capetownidrc.co.za)

# WMDA Vision for CGT



# Evolution Timeline of Patient Treatment



- Since the inception of the first donor registry 50 years ago, to facilitate unrelated stem cell transplant, the field has seen many advancements, from utilising umbilical cord blood as a source for transplants to the current day cell and gene therapy revolution.

# WMDA Mission

- We strive for a world where access to life-saving **cellular therapies** for all patients is assured and **donors'** rights and safety are protected. We work with our members to ensure reliable provision of **life-saving** cells while **promoting care and safety** for both patient and donor.
- Cellular therapies, means HSCT plus other cellular therapies including CAR-T, engineered grafts etc.
- Donors- means any person donating their cells and or tissues for the treatment of patient using a cellular therapy.
- Life saving, for patient use, one day this may be outside the field of haematological conditions.
- Donor and patient safety remains of paramount importance.

# WMDA Cell and Gene Therapy Committee



- Since 2021, the committee has;
- Published Donor Engagement in CGT Resource Kit
- Released guidance on donor consent for CGT research






[www.nature.com/bmt](http://www.nature.com/bmt)

**PERSPECTIVE** **OPEN**



## Remuneration of donors for cell and gene therapies: an update on the principles and perspective of the World Marrow Donor Association

Lina Hamad<sup>1</sup>, Salmah Mahmood Ahmed <sup>2</sup>✉, Eefke van Eerden<sup>3</sup>, Suzanna M. van Walraven <sup>4</sup>, World Marrow Donor Association Cellular Therapy Committee\* and Laura Machin <sup>5</sup>

© The Author(s) 2024

# WMMDA's CGT Ambition and Vision

- By 2028;
  - WMMDA is an important stakeholder in the growth of cell & gene therapies, focusing on safeguarding the well-being of donors.
  - WMMDA uses the collective voice of its members to advocate for the interests of donors and registries in regulation and policy where donor care and the international exchange of cellular products is concerned.
  - WMMDA gives its members insight, evidence and best practice to safeguard the safety and well-being of all donors in all steps related to the donation.

# Thank you to the WMDA Cell Gene Therapy Committee

- Chair - Salmah Mahmood Ahmed (Anthony Nolan)
- Chair elect- Thilo Mengling (DKMS)
- WMDA project support officer- Eefke van Eerden
- **Committee members**
  - Ann Woolfrey (Medpace)
  - Abeer Madbouly (NMDP)
  - Darren Hatton (Anthony Nolan)
  - David Allen (Canadian Blood Services)
  - Eva Frevel (DKMS)
  - Joannis Mytilineos (ZKRD)
  - Wouter Van't Hof (Cleveland Cord Blood Bank)
  - Arun Prasath (Singapore Cord Blood Bank)
  - Jay Feinberg (Gift of Life Biologics)



14<sup>th</sup>

International Donor Registry Conference  
& WMDA Meetings

25 – 29 June, 2024 – Cape Town, South Africa

*All patients & donors matter*

[www.capetownidrc.co.za](http://www.capetownidrc.co.za)

Advancing and facilitating the research, development and equitable clinical application of cell and gene therapies - what is our role in this?

Moderators: Salmah Ahmed, Jay Feinberg



# Introductions

- Global Perspective, Bambi Grilley, ISCT Chief Regulatory Officer
- South African and African perspective, Dr David Brittain,
- Pharmaceutical /Industry perspective, Dr Carla Kreissig, Cellex Cell Professionals, Germany
  
- We will have time for questions and panel discussion after all the presentations